Clinical trials: Dry Eye Disease (DED)
Dry Eye Disease
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.
To assess the safety, tolerability and efficacy of a single dose of OTX-CSI, a sustained release cyclosporine drug product, in subjects with dry eye disease.
- Trial name
- NCT04362670
- Testing
- OTX-CSI
- Where
- 15 sites in United States
- Volunteers
- 153 people
- Sponsor
- Ocular Therapeutix, Inc.
Dry Eye Disease (DED)
New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye
The goal of this prospective, non-randomized, non-comparative, monocentric PMCF study is to assess the performance of a new preservative-free combination of trehalose, sodium hyaluronate and NAAGA on DED at 6 months in 30…
- Trial name
- NCT06903741
- Testing
- T2769
- Where
- Bulgaria
- Volunteers
- 30 people
- Sponsor
- Laboratoires Thea
Dry Eye Disease (DED)
Vizol S DIGI EYE Efficacy and Safety Study in Patients With Dry Eye
The clinical investigation was intended to investigate the efficacy, ocular tolerability and safety of Vizol S DIGI EYE, a new eye drops, solution developed by JADRAN - GALENSKI LABORATORIJ d.d., in patients with moderate to…
- Trial name
- NCT07050446
- Testing
- Vizol S DIGI EYE eye drops, 0,9% saline solution, eye drops
- Where
- 3 sites in Serbia
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Jadran Galenski laboratorij d.d.
Dry Eye Disease (DED), Cataract Surgery
POST CATARACT SURGERY DRY EYE DISEASE
Cataract surgery is one of the most frequent and successful interventions currently undertaken in medicine. However, a significant number of patients who underwent cataract surgery still complain about postoperative symptoms…
- Trial name
- NCT07715266
- Testing
- NOX-01
- Where
- 2 sites in Spain
- Volunteers
- 33 people
- Sponsor
- NOXELIS
Evaporative Dry Eye Disease
Evaluation of MAF-1217 in Patients With DED
This is a pre-market, multicentre, double-blind, randomized, crossover, non-inferiority study comparing the efficacy of MAF-1217 and Cationorm® in adult patients with evaporative DED.
- Trial name
- NCT03833882
- Testing
- MAF1217, Cationorm
- Where
- 2 sites in Italy
- Volunteers
- 72 people
- Sponsor
- VISUfarma SpA
Dry Eye Disease, Endothelial Cell
A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine
The objective of this trial is to evaluate the effect of cyclosporine ophthalmic solution, 0.1% on corneal endothelial cell health in comparison to a hypotonic saline solution in subjects with Dry Eye Disease (DED)
- Trial name
- NCT06329661
- Testing
- Cyclosporine ophthalmic solution, 0.1%, Saline solution, 0.6%
- Where
- 6 sites in United States
- Volunteers
- 204 people
- Sponsor
- Novaliq GmbH
Dry Eye Disease
HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)
The purpose of this study is to determine whether SYL1001 ophthalmic solution is safe and effective in the treatment of signs and symptoms of Dry Eye Disease.
- Trial name
- NCT03108664
- Testing
- SYL1001 ophthalmic solution, Vehicle opthalmic solution
- Where
- 40 sites in Estonia, Germany and 4 more
- Volunteers
- 330 people
- Sponsor
- Sylentis, S.A.
Dry Eye Disease (DED)
Randomized Single Center Study to Evaluate Tolerability, Symptoms, and Visual Functional Outcomes With the Use of OTC Lubricating Eye Drops in Subjects With Dry Eye Disease
A study to evaluate the effect of over- the- counter (OTC) lubricating eye drops on tolerability, symptoms and visual outcomes in patients with dry eye disease (DED)
- Trial name
- NCT07676084
- Testing
- Preservative Free Polyethylene glycol 400 0.25%, Propylene Glycol (0.6%), Carboxymethylcellulose sodium 0.5%, Glycerin 1.0%, Polysorbate 80 0.5%
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Andover Research Eye Institute
Dry Eye Disease
A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.
Primary objective To evaluate the efficacy of 5 μg/mL and 10 μg/mL concentrations of the new formulation of rhNGF ophthalmic solution versus vehicle, in order to demonstrate superiority of at least 1 of the concentrations over…
- Trial name
- REDUCO (NCT06244316)
- Testing
- rhNGF 5 μg/mL, rhNGF 10 μg/mL
- Where
- 14 sites in United States, Italy
- Volunteers
- 317 people
- Sponsor
- Dompé Farmaceutici S.p.A
Dry Eye Disease
Safety and Efficacy of ST-100 (Vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease (DED)
A Phase 3 Multi-Center, Randomized, Double Masked, Vehicle Controlled Study to Assess the Safety and Efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed with Dry Eye Disease…
- Trial name
- NCT06178679
- Testing
- ST-100 (vezocolmitide), Vehicle
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- ORA, Inc.
Dry Eye Disease, Meibomian Gland Dysfunction
Feasibility of IPL Combined With RF for Treatment of DED Due to MGD
The purpose of this single-arm pilot study is to evaluate the feasibility and safety of combination therapy of intense pulsed light (IPL) and (Radiofrequency) RF for treatment of Dry eye disease (DED) due to Meibomian gland…
- Trial name
- NCT05487547
- Testing
- IPL_RF_MGX
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Lumenis Be Ltd.
Myopia, Dry Eye Disease (DED)
Study of Eye Fatigue From Digital Screens and Its Impact on Visual Performance in People With Normal Vision and Myopia, With and Without Dry Eye Symptoms and Signs
The goal of this observational study is to investigate the effects of eye fatigue induced by screen task on dry eye disease (DED) signs and symptoms, visual performance, and visual behavior in young adults with and without DED…
- Trial name
- RReye (NCT07844408)
- Testing
- Eye Exams, Ocular Biometry and Aberrometry, Wearing a Smartwatch
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Essilor International
Dry Eye Disease (DED)
Safety and Efficacy Study of RTP-008 (an Absorbable Tacrolimus Lacrimal Canalicular Plug) for Dry Eye
RTP-008, an absorbable tacrolimus lacrimal canalicular plug, targets two key pathophysiological mechanisms of dry eye: tear retention and local anti-inflammation.
- Trial name
- NCT07806240
- Testing
- RTP-008, Dissolvable Plug
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Raytone Bioscience Co.,Ltd
Dry Eye Disease (DED)
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).
- Trial name
- NCT03333057
- Testing
- NOV03
- Where
- 11 sites in United States
- Volunteers
- 336 people
- Sponsor
- Novaliq GmbH
Dry Eye
To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease
To assess the efficacy and safety of OTX-DED for the short-term treatment of signs and symptoms of dry eye disease.
- Trial name
- NCT04747977
- Testing
- OTX-DED
- Where
- 15 sites in United States
- Volunteers
- 172 people
- Sponsor
- Ocular Therapeutix, Inc.
Dry Eye Disease (DED)
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004
The objective of this trial is to evaluate safety and tolerability of CyclASol during long-term use in subjects with Dry Eye Disease.
- Trial name
- NCT04523142
- Testing
- CyclASol Ophthalmic Solution
- Where
- 14 sites in United States
- Volunteers
- 202 people
- Sponsor
- Novaliq GmbH
Dry Eye
An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)
Dry Eye Disease (DED) is a condition where the tear film of the eye becomes unstable and along with ocular surface inflammation and damage leads to inadequate tear production and eye lubrication.
- Trial name
- NCT06439394
- Testing
- Optive MEGA-3 (OM3)
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- AbbVie
Dry Eye Syndromes
CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)
The objective of this study was to compare the safety, efficacy, and tolerability of two different dose levels of CyclASol Ophthalmic Solutions to placebo (vehicle) and Restasis for the treatment of the signs and symptoms of Dry…
- Trial name
- NCT02617667
- Testing
- Cyclosporine A
- Where
- 4 sites in United States
- Volunteers
- 207 people
- Sponsor
- Novaliq GmbH
Dry Eye Disease (DED)
Dose-Finding Study of HUC1-394 in Participants With Dry Eye Disease
Clinical trial aims to determine the optimal dosing regimen by evaluating the efficacy and safety of HUC1-394 across different dosing frequencies in patients with moderate to severe dry eye disease.
- Trial name
- NCT07656688
- Testing
- HUC1-394
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Huons Co., Ltd.
Dry Eye Syndromes
Clinical Investigation to Assess the Efficacy and the Safety of VisuXL® Gel Administered in Patients Affected by Moderate DED
This is a post-market, european multicenter study. This is a randomized, cross-over, double blind study with competitive enrolment, aimed to enroll a total of 90 patients with a diagnosis of moderate dry eye disease (DED).
- Trial name
- NCT04485533
- Testing
- VisuXL® Gel, HYLO®
- Where
- 3 sites in France, Italy and 1 more
- Volunteers
- 90 people
- Sponsor
- VISUfarma SpA